trending Market Intelligence /marketintelligence/en/news-insights/trending/fTCA7XNhhQ-T5qIFJU3dBA2 content esgSubNav
In This List

Zynerba Pharmaceuticals to raise funds for cannabinoid-based treatments

Blog

Insight Weekly: Recession risk persists; Banks pull back from crypto; 2022 laggard stocks rally

Blog

Highlighting the Top Regional Aftermarket Research Brokers by Sector Coverage

Blog

Insight Weekly: Inflation eases; bank M&A slows; top companies boost market share

Blog

Insight Weekly: PE firms shift strategies; bank earnings kick off; bankruptcies plummet


Zynerba Pharmaceuticals to raise funds for cannabinoid-based treatments

Zynerba Pharmaceuticals Inc. is looking to raise funds for the continued development of its cannabinoid-based treatments ZYN002 and ZYN001.

The company is planning an underwritten offering of shares, and while pricing will occur at a later date, Zynerba did note that it will grant underwriters a 30-day option to purchase up to an additional 15% of the shares being offered.

Jefferies LLC and Piper Jaffray & Co. are acting as joint book-running managers for the offering.